CD44 and prostate carcinoma: Through the activation of the Hippo-YAP oncogene signalling pathway, CD44 promoted invasion and migration of docetaxel-resistant prostate cancer cells, which had a larger CD44+ population and positively correlated with poor survival of prostate cancer patients [128].